LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Guardant Health Inc

Closed

SectorHealthcare

63.62 0.46

Overview

Share price change

24h

Current

Min

63.15

Max

64.48

Key metrics

By Trading Economics

Income

-4.7M

-100M

Sales

29M

232M

Profit margin

-43.044

Employees

1,999

EBITDA

22M

-89M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

-2.48% downside

Market Stats

By TradingEconomics

Market Cap

2.2B

7.7B

Previous open

63.16

Previous close

63.62

News Sentiment

By Acuity

21%

79%

28 / 372 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Guardant Health Inc Chart

Past performance is not a reliable indicator of future results.

Related News

27 Aug 2025, 22:51 UTC

Earnings

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 Aug 2025, 23:57 UTC

Earnings

Trip.com Group 1H Rev $4.01B

27 Aug 2025, 23:57 UTC

Earnings

Trip.com Group 1H Adj EPS $1.84

27 Aug 2025, 23:57 UTC

Earnings

Trip.com Group 1H EPS $1.82

27 Aug 2025, 23:50 UTC

Market Talk

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 Aug 2025, 23:39 UTC

Earnings

Correction to Nvidia Earnings Article -- WSJ

27 Aug 2025, 22:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 Aug 2025, 22:59 UTC

Market Talk

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 Aug 2025, 22:58 UTC

Earnings

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 Aug 2025, 22:57 UTC

Earnings

South32 FY Free Cash Flow $192 Million

27 Aug 2025, 22:56 UTC

Earnings

South32 FY Total Capital Expenditure $1.35 Billion

27 Aug 2025, 22:56 UTC

Earnings

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 Aug 2025, 22:55 UTC

Earnings

South32 Net Cash $123 Million at June 30

27 Aug 2025, 22:54 UTC

Earnings

South32: Focused on Maintaining Strong Operating Momentum

27 Aug 2025, 22:53 UTC

Earnings

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 Aug 2025, 22:53 UTC

Earnings

South32 Extends Capital Management Program for 12 Months

27 Aug 2025, 22:52 UTC

Earnings

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 Aug 2025, 22:51 UTC

Earnings

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 Aug 2025, 22:51 UTC

Earnings

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 Aug 2025, 22:50 UTC

Earnings

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 Aug 2025, 22:50 UTC

Earnings

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 Aug 2025, 22:45 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 Aug 2025, 22:44 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 Aug 2025, 22:44 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 Aug 2025, 22:43 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 Aug 2025, 22:43 UTC

Earnings

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 Aug 2025, 22:42 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 Aug 2025, 22:42 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 Aug 2025, 22:40 UTC

Earnings

Sandfire Resources Net Debt $123 Million at June 30

27 Aug 2025, 22:40 UTC

Earnings

Sandfire Resources FY Underlying Ebitda $527.7 Million

Peer Comparison

Price change

Guardant Health Inc Forecast

Price Target

By TipRanks

-2.48% downside

12 Months Forecast

Average 61.86 USD  -2.48%

High 70 USD

Low 56 USD

Based on 16 Wall Street analysts offering 12 month price targets forGuardant Health Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

16

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

38.86 / 47.41Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

28 / 372 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.